Winner
nAMD Barometer Program: Leveraging Data to Re-examine Adherence in Ophthalmology
by ApotheCom, Inizio Medical for Bayer
Summary of work
In nAMD (neovascular age-related macular degeneration), suboptimal outcomes to anti-vascular endothelial growth factor (VEGF) treatment in the realworld have been observed for over ten years. The ophthalmology community has been lethargic in addressing the issue, believing it was simply an unavoidable consequence of delivering care in the realworld, and lacking understanding of the key modifiable barriers. The only way to shine new light on this long-standing issue was to generate and leverage new data on the root causes of these suboptimal outcomes, and to highlight evidence-based solutions that could genuinely improve outcomes in the clinic. This is what the nAMD Barometer Program set out to achieve – by first challenging the status quo, then investigating the barriers to treatment adherence, and finally by shaping clinical practice through interventions that drive changes in behaviour of both clinicians and patients.
To date, the program has successfully generated and leveraged data through newly established channels and partnerships with engaged stakeholders. The program has already successfully influenced clinical practice and policy at global, country and clinic levels via novel insights and targeted, patient-focused solutions. Adherence is gaining the attention it has long needed, and real-world outcomes will improve as a result.
Judges’ comments
ApotheCom and Bayer had put together a really thorough, clear and interesting submission. It had strong, quantified objectives and outputs and used the data in a meaningful way. A clear winner!
